الأبحاث
المنشورات
راجع قائمة المنشورات التي أعدّها أطباء مايو كلينك حول التليُّف المَجموعي الكلوي على محرك البحث PubMed، وهي خدمة تقدمها المكتبة الوطنية الأمريكية للطب.
- Lebwohl MG, et al. Nephrogenic systemic fibrosis. In: Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 5th ed. Elsevier; 2018. https://www.clinicalkey.com. Accessed April 15, 2021.
- Weinreb JC, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021; doi:10.1148/radiol.2020202903.
- Lunyera J, et al. Risk for nephrogenic systemic fibrosis after exposure to newer gadolinium agents: A systematic review. Annals of Internal Medicine. 2020; doi:10.7326/M20-0299.
- Ferri FF. Nephrogenic systemic fibrosis. In: Ferri's Clinical Advisor 2021. Elsevier; 2021. https://www.clinicalkey.com. Accessed April 15, 2021.
- Rudnick MR, et al. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease. https://www.uptodate.com/contents/search. Accessed April 15, 2021.
- AskMayoExpert. Nephrogenic systemic fibrosis. Mayo Clinic; 2019.
- Feehally J. Dermatologic manifestations of chronic kidney disease. In: Comprehensive Clinical Nephrology. 6th ed. Elsevier; 2019. https://www.clinicalkey.com. Accessed April 15, 2021.
- FDA drug safety communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warning. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body. Accessed April 15, 2021.
- Medical review (expert opinion). Mayo Clinic. April 26, 2021.
- American College of Radiology. ACR manual on contrast media 2021. https://www.acr.org/Clinical-Resources/Contrast-Manual. Accessed April 27, 2021.